Literature DB >> 20817624

Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis.

Antonia V Bennett1, Donald L Patrick, James F Lymp, Todd C Edwards, Christopher H Goss.   

Abstract

BACKGROUND: Patient reporting of symptoms in a questionnaire with a 7-day recall period is expected to differ from reporting in daily symptom diaries.
METHODS: 38 patients with cystic fibrosis (CF) completed 77 week-long symptom diaries. Each diary day comprised 13 symptom items with 5-point response scales. Days 1-6 of the diary had a 24-hour recall period. Day 7 had a 7-day recall period. Concordance of 7-day recall with summary descriptors of daily reports (e.g. mean, maximum) was examined and ability of 7-day recall and mean of daily reports to discriminate between well and ill periods of health compared.
RESULTS: The average difference in scores was less than 0.25 response scale points. 7-day recall was most concordant with the mean of daily reports. Discriminant ability was comparable.
CONCLUSIONS: In this study sample, a questionnaire with 7-day recall provided information similar to a daily diary about the week-long experience of CF symptoms.
Copyright © 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20817624     DOI: 10.1016/j.jcf.2010.08.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  13 in total

1.  Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation.

Authors:  William A Wood; Allison M Deal; Antonia V Bennett; Sandra A Mitchell; Amy P Abernethy; Ethan Basch; Charlotte Bailey; Bryce B Reeve
Journal:  J Pain Symptom Manage       Date:  2014-08-13       Impact factor: 3.612

2.  Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

Authors:  D R Vandevanter; A Yegin; W J Morgan; S J Millar; D J Pasta; M W Konstan
Journal:  J Cyst Fibros       Date:  2011-07-30       Impact factor: 5.482

3.  Initial development and pilot testing of observer-reported outcomes (ObsROs) for children with cystic fibrosis ages 0-11years.

Authors:  T C Edwards; J Emerson; A Genatossio; S McNamara; C Goss; D L Patrick; F Onchiri; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2018-02-01       Impact factor: 5.482

4.  Comparison of 7-day and repeated 24-h recall of type 2 diabetes.

Authors:  A V Bennett; D L Patrick; D M Bushnell; C F Chiou; P Diehr
Journal:  Qual Life Res       Date:  2010-11-19       Impact factor: 4.147

5.  Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Authors:  Tito R Mendoza; Amylou C Dueck; Antonia V Bennett; Sandra A Mitchell; Bryce B Reeve; Thomas M Atkinson; Yuelin Li; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Richard L Piekarz; Charles S Cleeland; Jeff A Sloan; Deborah Schrag; Ethan Basch
Journal:  Clin Trials       Date:  2017-03-20       Impact factor: 2.486

6.  Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.

Authors:  Bradley S Quon; Donald L Patrick; Todd C Edwards; Moira L Aitken; Ronald L Gibson; Alan Genatossio; Sharon McNamara; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2012-01-04       Impact factor: 5.482

7.  A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.

Authors:  Christopher H Goss; Sonya L Heltshe; Natalie E West; Michelle Skalland; Don B Sanders; Raksha Jain; Tara L Barto; Barbra Fogarty; Bruce C Marshall; Donald R VanDevanter; Patrick A Flume
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 21.405

8.  Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.

Authors:  Kelly P McCarrier; Thomas M Atkinson; Kendra P A DeBusk; Astra M Liepa; Michael Scanlon; Stephen Joel Coons
Journal:  Clin Ther       Date:  2016-04-01       Impact factor: 3.393

9.  Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

Authors:  Donald R VanDevanter; Michael W Konstan
Journal:  Clin Investig (Lond)       Date:  2012

10.  Health care costs related to home spirometry in the eICE randomized trial.

Authors:  Natalie Franz; Hannah Rapp; Ryan N Hansen; Laura S Gold; Christopher H Goss; Noah Lechtzin; Larry G Kessler
Journal:  J Cyst Fibros       Date:  2021-03-12       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.